Minarik, J., Pika, T., Radocha, J., Jungova, A., Straub, J., Jelinek, T., . . . Hajek, R. (2021). Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer.
Citação norma ChicagoMinarik, Jiri, et al. "Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice." BMC Cancer 2021.
MLA CitationMinarik, Jiri, et al. "Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice." BMC Cancer 2021.